Laboratoires Pierre Fabre

Nowadays, Laboratoires Pierre Fabre is a topic that has gained great importance in today's society. For years, Laboratoires Pierre Fabre has been the subject of debate, analysis and reflection in different areas, from politics to popular culture. However, in recent times, interest in Laboratoires Pierre Fabre has grown exponentially, becoming a highly relevant topic in public conversation. Whether due to its impact on people's daily lives, its influence on the development of technology or its role in the evolution of human thought, Laboratoires Pierre Fabre has become a fundamental element to take into account in modern society. In this article, we will explore different aspects related to Laboratoires Pierre Fabre, analyzing its influence, its implications and its relevance in today's world.

Pierre Fabre S.A.
Company typePrivate limited company
IndustryPharmaceutical
Founded1962 (1962)
HeadquartersCastres, France[1]
Area served
Worldwide
Key people
  • Eric Ducournau
  • (President and CEO)
Number of employees
13,000 (2015) (Homepage)
Websitewww.pierre-fabre.com

Laboratoires Pierre Fabre (French pronunciation: [labɔʁatwaʁ pjɛʁ fabʁ]) is a French multinational pharmaceutical and cosmetics company headquartered in the city of Castres, Midi-Pyrénées, France.[2]

History

Founded in 1962 by Pierre Fabre (1926-2013),[2] the company is present in over 130 countries.

Olivier Bohuon was Chief Executive from September 2010 to April 2011.[3]

Business

The company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products.

Pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover).[citation needed]

The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international).[2]

Laboratories Pierre Fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in France.[2]

Products

Pierre Fabre is best known for its vinorelbine (Navelbine),[4][5] an anticancer drug[6] of the vinca alkaloid class.[7][8][9]

They also developed vinflunine,[10] a fluorinated vinca alkaloid derivative[11][12] available in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen."[13]

The Pierre Fabre Foundation

The Pierre Fabre Foundation was recognized as a public utility in 1999,[14] and its mission is to enable communities from less advanced and emerging countries, as well as those plunged into severe crisis by political or economic upheaval and/or natural disaster, to access the quality and levels of everyday health care and the widely-used drugs defined by the WHO and other organisations as essential to human health.[15]

References

  1. ^ "Company Overview of Pierre Fabre S.A." Archived from the original on January 1, 2009. Retrieved December 9, 2014.
  2. ^ a b c d "Pierre Fabre, founder of pharmaceutical giant, dies". Agence France Presse. France 24. 2013-07-20. Archived from the original on 2013-07-23. Retrieved 2013-08-17.
  3. ^ "Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA". FierceBiotech. Retrieved 2020-01-29.
  4. ^ Ngo, Quoc Anh; Roussi, Fanny; Cormier, Anthony; Thoret, Sylviane; Knossow, Marcel; Guénard, Daniel; Guéritte, Françoise (2009). "Synthesis and biological evaluation of Vinca alkaloids and phomopsin hybrids". Journal of Medicinal Chemistry. 52 (1): 134–142. doi:10.1021/jm801064y. PMID 19072542.
  5. ^ Keglevich, Péter; Hazai, Laszlo; Kalaus, György; Szántay, Csaba (2012). "Modifications on the basic skeletons of vinblastine and vincristine". Molecules. 17 (5): 5893–5914. doi:10.3390/molecules17055893. PMC 6268133. PMID 22609781.
  6. ^ Faller, Bryan A.; Pandi, Trailokya N. (2011). "Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer". Clinical Medicine Insights: Oncology. 5: 131–144. doi:10.4137/CMO.S5074. PMC 3117629. PMID 21695100.
  7. ^ van der Heijden, Robert; Jacobs, Denise I.; Snoeijer, Wim; Hallard, Didier; Verpoorte, Robert (2004). "The Catharanthus alkaloids: Pharmacognosy and biotechnology". Current Medicinal Chemistry. 11 (5): 607–628. doi:10.2174/0929867043455846. PMID 15032608.
  8. ^ Raviña, Enrique (2011). "Vinca alkaloids". The evolution of drug discovery: From traditional medicines to modern drugs. John Wiley & Sons. pp. 157–159. ISBN 9783527326693.
  9. ^ Cooper, Raymond; Deakin, Jeffrey John (2016). "Africa's gift to the world". Botanical Miracles: Chemistry of Plants That Changed the World. CRC Press. pp. 46–51. ISBN 9781498704304.
  10. ^ "Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status" (Press release). Bristol-Myers Squibb. November 23, 2007. Archived from the original on May 28, 2008. Retrieved June 27, 2008.
  11. ^ Fahy, Jacques; Duflos, Alain; Ribet, Jean-Paul; Jacquesy, Jean-Claude; Berrier, Christian; Jouannetaud, Marie-Paule; Zunino, Fabien (1997). "Vinca Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives". J. Am. Chem. Soc. 119 (36): 8576–8577. doi:10.1021/ja971864w.
  12. ^ Kruczynski, Anna; Barret, Jean-Marc; Etiévant, Chantal; Colpaert, Francis; Fahy, Jacques; Hill, Bridget T. (1998). "Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid". Biochem. Pharmacol. 55 (5): 635–648. doi:10.1016/S0006-2952(97)00505-4. PMID 9515574.
  13. ^ "Vinflunine, solution concentration for I.V. infusion, 50 mg in 2 mL and 250 mg in 10 mL (as ditartrate), Javlor® – November 2011". Pharmaceutical Benefits Scheme. March 16, 2012. Retrieved June 22, 2017.
  14. ^ pbouchayer. "History". Fondation Pierre Fabre. Retrieved 2021-09-19.
  15. ^ pbouchayer. "DNA". Fondation Pierre Fabre. Retrieved 2021-09-19.


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.